Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:25:05 ON 26 FEB 2008

=> fil capl

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 12:25:21 ON 26 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 25 Feb 2008 (20080225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.69

FILE 'REGISTRY' ENTERED AT 12:25:23 ON 26 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2008 HIGHEST RN 1005378-46-0
DICTIONARY FILE UPDATES: 25 FEB 2008 HIGHEST RN 1005378-46-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566291.str





chain nodes :
7 8 9 10 11 15 17 18 19
ring nodes :
1 2 3 4 5 6 23 24 25 26 27 28 29 30 31 32 33 34
chain bonds :
2-17 5-7 7-8 8-9 9-10 9-15 10-11 17-18 18-19 19-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 23-24 23-28 24-25 25-26 26-27 27-28 29-30
29-34 30-31 31-32 32-33 33-34
exact/norm bonds :
2-17 5-7 7-8 9-10 9-15 10-11 17-18 18-19 19-29
exact bonds :
8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 23-24 23-28 24-25 25-26 26-27 27-28 29-30
29-34 30-31 31-32 32-33 33-34
isolated ring systems :
containing 1 : 23 :

G1:C,O,S

G2:C,H

G3:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 23:Atom 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S

G2 C,H

G3 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 12:25:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 311610 TO ITERATE

0.6% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 6199834 TO 6264566
PROJECTED ANSWERS: 5173 TO 7291

L2 2 SEA SSS SAM L1

=> log h
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.46 1.15

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:26:06 ON 26 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 12:28:28 ON 26 FEB 2008
FILE 'REGISTRY' ENTERED AT 12:28:28 ON 26 FEB 2008
COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	1.15

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.92	1.61

FILE 'REGISTRY' ENTERED AT 12:29:11 ON 26 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 FEB 2008 HIGHEST RN 1005378-46-0
DICTIONARY FILE UPDATES: 25 FEB 2008 HIGHEST RN 1005378-46-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566291.str





chain nodes :
7 8 9 10 11 15 17 18 19
ring nodes :
1 2 3 4 5 6 23 24 25 26 27 28 29 30 31 32 33 34
chain bonds :
2-17 5-7 7-8 8-9 9-10 9-15 10-11 17-18 18-19 19-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 23-24 23-28 24-25 25-26 26-27 27-28 29-30
29-34 30-31 31-32 32-33 33-34
exact/norm bonds :
2-17 5-7 7-8 9-10 9-15 10-11 17-18 18-19 19-29
exact bonds :
8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 23-24 23-28 24-25 25-26 26-27 27-28 29-30
29-34 30-31 31-32 32-33 33-34
isolated ring systems :
containing 1 : 23 :

G1:C,O,S

G2:C,H

G3:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 23:Atom 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom

```
L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sam
SAMPLE SEARCH INITIATED 12:29:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     9989 TO ITERATE

 20.0% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       193790 TO   205770
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 12:29:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   201119 TO ITERATE

100.0% PROCESSED   201119 ITERATIONS                              67 ANSWERS
SEARCH TIME: 00.00.03

L5           67 SEA SSS FUL L3

=> d scan
```

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenepropanoic acid, 2-ethyl-4-[3-[2-(3-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-, ethyl ester
MF C29 H32 F3 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenepropanoic acid, 2-methyl-4-[(3R)-3-[2-(2-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-
MF C26 H26 F3 N O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenepropanoic acid, 4-[(3S)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]-2-methyl-, methyl ester
MF C28 H33 N O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenepropanoic acid, 4-[2-[(3-phenyl-6-benzofuranyl)oxy]ethoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]-
MF C32 H28 N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenepropanoic acid, 4-[1-(aminomethyl)-4-phenyl-4-(3-pyridinyl)butyl]-, methyl ester, (R*,R*)- (9CI)
MF C26 H30 N2 O2

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Acetic acid, [4-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-[[[6-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-2-pyridinyl]carbonyl]amino]phenoxy]-, ethyl ester (9CI)
MF C33 H36 Cl N3 O7 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 67 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzenepropanoic acid, 2-ethyl-4-[[(3S)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butyl]thio]-
MF C28 H33 N O3 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> fil capl
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.82     180.43

FILE 'CAPLUS' ENTERED AT 12:30:25 ON 26 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Feb 2008  VOL 148 ISS 9
FILE LAST UPDATED: 25 Feb 2008  (20080225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d histr
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n


=> s l5 not (2008/so or 2007/so or 2006/so or 2005/so)
            14 L5
         95777 2008/SO
        870550 2007/SO
        930316 2006/SO
        882187 2005/SO
L6          13 L5 NOT (2008/SO OR 2007/SO OR 2006/SO OR 2005/SO)

=> s l5
L7          14 L5

=> fil capl
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      10.88     191.31

FILE 'CAPLUS' ENTERED AT 12:33:34 ON 26 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
```

FILE COVERS 1907 - 26 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 25 Feb 2008 (20080225/ED)


```
=> s l5
L8          14 L5

=> s l8 not (2008/so or 2007/so or 2006/so or 2005/so)
         95777 2008/SO
        870550 2007/SO
        930316 2006/SO
        882187 2005/SO
L9          13 L8 NOT (2008/SO OR 2007/SO OR 2006/SO OR 2005/SO)

=> d l9 ibib hitstr abs 1-13
```

L9 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1470010 CAPLUS
DOCUMENT NUMBER: 148:100384
TITLE: Preparation of 1,3-diphenylpropane derivatives, particularly 2-[4-(3-oxo-3-phenylpropyl)phenoxy]-2-methylpropanoic acids and related derivatives, as PPAR agonists for treating diseases especially dyslipidemia
INVENTOR(S): Delhomel, Jean-Francois; Hanf, Remy; Caumont-Bertrand, Karine
PATENT ASSIGNEE(S): Genfit, Fr.
SOURCE: PCT Int. Appl., 97pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007147880	A1	20071227	WO 2007-EP56225	20070621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2902789	A1	20071228	FR 2006-5540	20060621

PRIORITY APPLN. INFO.: FR 2006-5540 A 20060621
OTHER SOURCE(S): MARPAT 148:100384
IT 1000336-74-2P, 2-[2,6-Dimethyl-4-[3-[(pyridin-3-yl)methoxy]-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2-methylpropanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 1,3-diphenylpropane derivs. as PPAR activators for treating diseases especially dyslipidemia)
RN 1000336-74-2 CAPLUS
CN Propanoic acid, 2-[2,6-dimethyl-4-[3-(3-pyridinylmethoxy)-3-[4-(trifluoromethoxy)phenyl]propyl]phenoxy]-2-methyl- (CA INDEX NAME)



GI



I



II

AB Title compds. I [X1 = halo, R1, G1R1; X2 = halo, R2, G2R2; X3 = R3, G3R3; X4 = halo, R4, G4R4; X5 = R5, G5R5; R1 = haloalkyl; R2 = H, alkyl; R3-R5 = independently H, (un)substituted alkyl; G1-G5 = independently O, S; with at least one of X3-X5 = R3, G3R3, R4, G4R4, R5, G5R5 in which G3-G5 = defined as above and R3-R5 = independently alkyl substituted with 1-2 substituents selected from CO2H and derivs., CONH2 and derivs., SO3H, SO2NH2 and derivs.; A = CR6R7, CO, C:N-OH, C:N-OR8; R6 = H, alkyl, OR8; R7 = alkyl, OH, OR8; R8 = independently alkyl substituted with an aryl or cycloalkyl group; D = CH2, CHY; Y = O- or S-heterocycle; and their stereoisomers, racemates, geometrical isomers, tautomers, salts, hydrates, solvates, solid forms and their mixts.] were prepared as PPAR activators, especially agonists, for treating dyslipidemia, diabetes type II and related diseases. Thus, reduction of 2-[2,6-dimethyl-4-[3-[4-(trifluoromethylthio)phenyl]-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid with triethylsilane in DCM in the presence of TFA at room temperature gave the acid II (m.p. = 83-85°). Selected I were hPPARα, hPPARγ, and/or hPPAδ activators in an induced luciferase activity via hPPARα/Gal4, hPPARγ/Gal4, and hPPARδ/Gal4 transactivation assay. I displayed hypolipemic properties by lowering the plasmatic cholesterol and triglycerides rates. I are useful for treating diabetes type II, dyslipidemia, pathologies associated with metabolic syndrome, cardiovascular diseases, etc.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:182607 CAPLUS
DOCUMENT NUMBER: 142:279949
TITLE: Preparation of aryloxyalkoxyphenylalkanoic acids and analogs, as PPAR modulators, especially PPAR agonists
INVENTOR(S): Gonzalez Valcarcel, Isabel Cristina; Mantlo, Nathan Bryan; Shi, Qing; Wang, Minmin; Winneroski, Leonard Larry, Jr.; Xu, Yanping; York, Jeremy Schulenburg
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 603 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005019151	A1	20050303	WO 2004-US24381		20040817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2536089	A1	20050303	CA 2004-2536089		20040817
EP 1660428	A1	20060531	EP 2004-779442		20040817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2007502815	T	20070215	JP 2006-523861		20040817
US 2006257987	A1	20061116	US 2006-566291		20060125
PRIORITY APPLN. INFO.:			US 2003-496549P	P	20030820
			WO 2004-US24381	W	20040817

OTHER SOURCE(S): MARPAT 142:279949
IT 847345-57-7P, 3-[4-[[(S)-3-[4-Ethyl-2-(pyridin-2-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid 847345-60-2P, 3-[4-[[(S)-3-[4-Ethyl-2-(pyridin-3-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid 847345-63-5P, 3-[4-[[(S)-3-[4-Ethyl-2-(pyridin-4-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid 847345-65-7P, 3-[4-[[(S)-3-[4-Chloro-2-(pyridin-2-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid 847347-31-3P, (R)-3-[4-[3-[4-Ethyl-2-[(pyridin-2-yl)carbonyl]phenoxy]butoxy]-2-methylphenyl]propionic acid 847348-30-5P, (R)-3-[4-[3-[4-Chloro-2-(pyridin-3-yl)phenoxy]butoxy]-2-methylphenyl]propionic acid 847349-20-6P, (R)-3-[2-Ethyl-4-[3-[4-ethyl-2-(pyridin-2-yl)phenoxy]butoxy]phenyl]propionic acid 847349-23-9P, (R)-3-[2-Methyl-4-[3-[[2-(pyridin-2-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid 847349-26-2P, (R)-3-[2-Methyl-4-[3-[[2-(pyridin-4-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid 847349-30-8P, (R)-3-[2-Ethyl-4-[3-[[2-(pyridin-2-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid 847349-32-0P, (R)-3-[2-Ethyl-4-[3-[[2-(pyridin-4-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid 847349-37-5P, (R)-3-[4-[3-[4-Chloro-2-(pyridin-4-

yl)phenoxy]butoxy]-2-methylphenyl]propionic acid 847349-43-3P, (R)-3-[2-Ethyl-4-[3-[[2-(pyridin-3-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid 847351-60-4P, (S)-3-[2-Ethyl-4-[[3-[4-ethyl-2-(pyridin-2-yl)phenoxy]butyl]sulfanyl]phenyl]propionic acid 847352-14-1P, (R)-3-[4-[3-[4-Ethyl-2-(pyridin-2-yl)phenoxy]butoxy]-2-methylphenyl]propionic acid 847352-15-2P, (R)-[[4-[3-[4-Ethyl-2-(pyridin-2-yl)phenoxy]butoxy]-2-methylphenyl]sulfanyl]ethanoic acid 847352-16-3P, (R)-3-[4-[3-[4-Chloro-2-(pyridin-2-yl)phenoxy]butoxy]-2-methylphenyl]propionic acid 847352-17-4P, (R)-3-[4-[3-[4-Ethyl-2-(pyridin-3-yl)phenoxy]butoxy]-2-methylphenyl]propionic acid 847352-18-5P, (R)-3-[4-[3-[4-Ethyl-2-(pyridin-4-yl)phenoxy]butoxy]-2-methylphenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR agonist; preparation of alkoxyphenylalkanoic acids and analogs as PPAR agonists)

RN 847345-57-7 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847345-60-2 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-ethyl-2-(3-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847345-63-5 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-ethyl-2-(4-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847345-65-7 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-chloro-2-(2-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847347-31-3 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-ethyl-2-(2-pyridinylcarbonyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847348-30-5 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-chloro-2-(3-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-20-6 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[(3R)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-23-9 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[(3R)-3-[2-(2-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-26-2 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[(3R)-3-[2-(4-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-30-8 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[(3R)-3-[2-(2-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-32-0 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[(3R)-3-[2-(4-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-37-5 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-chloro-2-(4-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-43-3 CAPLUS

CN Benzenepropanoic acid, 2-ethyl-4-[(3R)-3-[2-(3-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847351-60-4 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[[(3S)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 847352-14-1 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847352-15-2 CAPLUS
CN Acetic acid, [[4-[(3R)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]-2-methylphenyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847352-16-3 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-chloro-2-(2-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847352-17-4 CAPLUS

CN Benzenepropanoic acid, 4-[(3R)-3-[4-ethyl-2-(3-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 847352-18-5 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-ethyl-2-(4-pyridinyl)phenoxy]butoxy]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 847345-59-9P, 3-[4-[[(S)-3-[4-Ethyl-2-(pyridin-2-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid methyl ester
847345-62-4P, 3-[4-[[(S)-3-[4-Ethyl-2-(pyridin-3-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid methyl ester
847345-67-9P, 3-[4-[[(S)-3-[4-Chloro-2-(pyridin-2-yl)phenoxy]butyl]oxy]-2-methylphenyl]propionic acid methyl ester
847347-32-4P, (R)-3-[4-[3-[4-Ethyl-2-[(pyridin-2-yl)carbonyl]phenoxy]butoxy]-2-methylphenyl]propionic acid methyl ester
847349-22-8P, 3-[2-Ethyl-4-[3-[4-ethyl-2-(pyridin-2-yl)phenoxy]butoxy]phenyl]propionic acid ethyl ester 847349-25-1P, 3-[2-Methyl-4-[3-[[2-(pyridin-2-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of alkoxyphenylalkanoic acids and analogs as PPAR agonists)

RN 847345-59-9 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]-2-

methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847345-62-4 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-ethyl-2-(3-pyridinyl)phenoxy]butoxy]-2-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847345-67-9 CAPLUS
CN Benzenepropanoic acid, 4-[(3S)-3-[4-chloro-2-(2-pyridinyl)phenoxy]butoxy]-2-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847347-32-4 CAPLUS
CN Benzenepropanoic acid, 4-[(3R)-3-[4-ethyl-2-(2-pyridinylcarbonyl)phenoxy]butoxy]-2-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-22-8 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[3-[4-ethyl-2-(2-pyridinyl)phenoxy]butoxy]-, ethyl ester (CA INDEX NAME)



RN 847349-25-1 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[3-[2-(2-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-, methyl ester (CA INDEX NAME)



IT 847349-29-5, 3-[2-Methyl-4-[3-[[2-(pyridin-4-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid methyl ester
847349-31-9, 3-[2-Ethyl-4-[3-[[2-(pyridin-2-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid ethyl ester
847349-33-1, (R)-3-[2-Ethyl-4-[3-[[2-(pyridin-4-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid ethyl ester
847349-40-0, 3-[4-[3-[4-Chloro-2-(pyridin-4-yl)phenoxy]butoxy]-2-methylphenyl]propionic acid methyl ester 847349-45-5, 3-[2-Ethyl-4-[3-[[2-(pyridin-3-yl)-4-trifluoromethylphenyl]oxy]butoxy]phenyl]propionic acid ethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of alkoxyphenylalkanoic acids and analogs as PPAR agonists)

RN 847349-29-5 CAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[3-[2-(4-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-, methyl ester (CA INDEX NAME)



RN 847349-31-9 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[3-[2-(2-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-, ethyl ester (CA INDEX NAME)



RN 847349-33-1 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[(3R)-3-[2-(4-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847349-40-0 CAPLUS
CN Benzenepropanoic acid, 4-[3-[4-chloro-2-(4-pyridinyl)phenoxy]butoxy]-2-methyl-, methyl ester (CA INDEX NAME)



RN 847349-45-5 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[3-[2-(3-pyridinyl)-4-(trifluoromethyl)phenoxy]butoxy]-, ethyl ester (CA INDEX NAME)



GI



I



II

AB Title compds. I [wherein B = -A1-CR4R5-Q; X = -A2-(CHR2)-Y-(CHR1)-A3-Z; A1 = a bond, CH2, O, S, and wherein A1and R4 or A1 and R5 form a 3- to 6-membered carbocyclyl when A1 = C; A2, A3 = independently CH2, O, S; D, E, F, G, H = independently CH, or substituted C bearing A2 and R3; or at least one of D, E, F, G, H is N and each others being CH or substituted C bearing A2 and R3; Q = CO2H and derivs., carboxamido, sulfonamido, etc.; Y = a bond, cyclo/alkyl; Z = aryl, 5- to 10-membered heteroaryl, biaryl, (un)substituted biheteroaryl; n = 1-4; R1, R2 = independently H, halo/cyclo/alkyl; or R1 and R2 form a 4- to 8-membered nonarom. carbocyclic ring; and wherein at least one of R1 and R2 is cyclo/alkyl; R3 = H, NO2, CN, OH, halo, cyclo/halo/alkyl, haloalkyloxy, aryloxy, alkoxy; R4, R5 = independently H, alkyl; and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof] were prepared as PPAR modulators, especially PPAR agonists. A multistep synthesis is given for acid II. I displayed IC50 and EC50 in the range of about 1 nM to about 5 μM for binding to PPAR gamma, and/or delta receptors. I are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964313 CAPLUS
DOCUMENT NUMBER: 138:55745
TITLE: Preparation of substituted 3-phenyl-2-alkoxypropanoic acids and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions
INVENTOR(S): Brooks, Dawn Alisa; Warshawsky, Alan M.; Montrose-Rafezadeh, Chahrzad; Reifel-Miller, Anne; Prieto, Lourdes; Rojo, Isabel; Martin, Jose Alfredo; Gonzales Garcia, Maria Rosario; Torrado, Alicia; Ferritto Crespo, Rafael; Lamas-Peteira, Carlos; Martin-Ortega Finger, Maria; Ardecky, Robert J.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Ligand Pharmaceuticals Incorporated
SOURCE: PCT Int. Appl., 458 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100813	A2	20021219	WO 2002-US16950	20020530
WO 2002100813	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449256	A1	20021219	CA 2002-2449256	20020530
AU 2002312147	A1	20021223	AU 2002-312147	20020530
EE 200400001	A	20040216	EE 2004-1	20020530
EP 1392637	A2	20040303	EP 2002-739503	20020530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010190	A	20040406	BR 2002-10190	20020530
CN 1543451	A	20041103	CN 2002-811530	20020530
HU 2004000280	A2	20050128	HU 2004-280	20020530
HU 2004000280	A3	20060130		
JP 2005509590	T	20050414	JP 2003-503584	20020530
NZ 529351	A	20060127	NZ 2002-529351	20020530
IN 2003KN01456	A	20060414	IN 2003-KN1456	20031110
ZA 2003008863	A	20050214	ZA 2003-8863	20031113
US 2005020684	A1	20050127	US 2003-479262	20031201
US 7192982	B2	20070320		
MX 2003PA11201	A	20040226	MX 2003-PA11201	20031204
US 2007276138	A1	20071129	US 2006-637223	20061211

PRIORITY APPLN. INFO.:	US 2001-297144P	P	20010607
	WO 2002-US16950	W	20020530
	US 2003-479262	A1	20031201

OTHER SOURCE(S): MARPAT 138:55745
IT 477982-80-2P, (2S)-2-Methoxy-3-[4-[3-[4-(pyridin-3-

yl)phenoxy]propoxy]phenyl]propionic acid 477982-81-3P,
(2S)-2-Methoxy-3-[4-[3-[4-(pyridin-4-yl)phenoxy]propoxy]phenyl]propionic
acid 477984-02-4P, (2S)-2-Methoxy-3-[4-[2-[4-[(pyridine-3-
carbonyl)amino]phenoxy]ethoxy]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(PPAR modulator; preparation of substituted (phenyl)(alkoxy)propanoic acids
and analogs as PPAR modulators for treatment of diabetes and related
conditions)

RN 477982-80-2 CAPLUS
CN Benzenepropanoic acid, α-methoxy-4-[3-[4-(3-
pyridinyl)phenoxy]propoxy]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 477982-81-3 CAPLUS
CN Benzenepropanoic acid, α-methoxy-4-[3-[4-(4-
pyridinyl)phenoxy]propoxy]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 477984-02-4 CAPLUS
CN Benzenepropanoic acid, α-methoxy-4-[2-[4-[(3-
pyridinylcarbonyl)amino]phenoxy]ethoxy]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II

AB Title compds. I [wherein Ar = (un)substituted aryl; Q = covalent bond, CH2, CH2CH2, CH2CH2CH2, or CH2CH2CH2CH2; W = (un)substituted (hetero)alkylene from 2-10 atoms in length in which 1 or more methylene groups have been replaced with CH=CH, C.tplbond.C, O, CO, NR7, NR7CO, C(=NOH), S, SO, SO2, or CHNR7R8; ring A is optionally substituted with up to 4 substituents in addition to R1; R1 = (CH2)nCH(OR2)(CH2)mE, CH=C(OR2)(CH2)mE, (CH2)nCHY(CH2)mE, or CH=CY(CH2)mE; E = CO2R3, alkylnitrile, carboxamide, or (un)substituted sulfonamide, acylsulfonamide, or tetrazole; R2 = H, haloalkyl, COR4, CO2R4, CONR5R6, CSR4, CSOR4, CSNR5R6, or (un)substituted aliphatic group, aralkyl, or aryl; Y = O, CH2, CH2CH2, or CH=CH bonded ortho to R1 on ring A; R3-R8 = independently H or (un)substituted aliphatic group or aryl; m and n = independently 0-2; or pharmaceutically acceptable salts, hydrates, stereoisomers, or solvates thereof] were prepared by solution phase and solid phase synthetic methods as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, (S)-2-methoxy-3-hydroxyphenylpropanoic acid Et ester was treated with Ph triflimide to give the 4-trifluoromethanesulfonyloxyphenyl derivative (97%). Substitution with propargyl alc. in the presence of PdCl2(PPh3)2 and TEA in DMF afforded the 4-(3-hydroxyprop-1-ynyl)phenyl intermediate (32%), which was

coupled with 4-phenylphenol using the Mitsunobu procedure to give II. Binding and cotransfection studies showed that many of the compds. of the invention are selective PPARγ agonists or PPARα/PPARγ co-agonists (no data). Thus, I are useful for the treatment of hyperglycemia, dyslipidemia, Type I or II diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, polycystic ovarian syndrome, anorexia nervosa, cardiovascular disease or other diseases where insulin resistance is a component (no data).

L9 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:964190 CAPLUS
DOCUMENT NUMBER: 138:39272
TITLE: Preparation of 3-(oxazolylalkoxyphenyl)propionic acids and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions
INVENTOR(S): Gossett, Lynn Stacy; Green, Jonathan Edward; Henry, James Robert; Jones, Winton Dennis, Jr.; Matthews, Donald Paul; Shen, Quan Rong; Smith, Daryl Lynn; Vance, Jennifer Ann; Warshawsky, Alan M.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002100403	A1	20021219	WO 2002-US15143		20020524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2448552	A1	20021219	CA 2002-2448552		20020524
AU 2002316105	A1	20021223	AU 2002-316105		20020524
NZ 529550	A	20031219	NZ 2002-529550		20020524
EP 1401434	A1	20040331	EP 2002-746380		20020524
EP 1401434	B1	20061115			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002010167	A	20040406	BR 2002-10167		20020524
HU 2004000268	A2	20040728	HU 2004-268		20020524
JP 2005502600	T	20050127	JP 2003-503224		20020524
CN 1578659	A	20050209	CN 2002-815453		20020524
AT 345128	T	20061215	AT 2002-746380		20020524
ES 2275887	T3	20070616	ES 2002-746380		20020524
US 2005075378	A1	20050407	US 2003-477405		20031112
US 7282501	B2	20071016			
ZA 2003009059	A	20050810	ZA 2003-9059		20031120
MX 2003PA10903	A	20040217	MX 2003-PA10903		20031127
IN 2003KN01573	A	20060317	IN 2003-KN1573		20031203
PRIORITY APPLN. INFO.:			US 2001-296701P	P	20010607
			WO 2002-US15143	W	20020524

OTHER SOURCE(S): MARPAT 138:39272
IT 478546-21-3P, 3-[4-[2-(Biphenyl-4-yloxy)ethoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-22-4P, 3-[4-[2-(Biphenyl-3-yloxy)ethoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-23-5P, 3-[4-[2-(4-Phenoxyphenoxy)ethoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-24-6P, 3-[4-[2-(3-Phenylbenzofuran-6-yloxy)ethoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid

478546-25-7P, 3-[4-[2-(6-Methoxynaphthalen-2-yloxy)ethoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-32-6P, 3-[4-[4-(Biphenyl-3-yloxy)butoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-33-7P, 3-[4-[4-(4-Phenoxyphenoxy)butoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-34-8P, 3-[4-[4-(3-Phenylbenzofuran-6-yloxy)butoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl] propionic acid 478546-35-9P, 3-[4-[4-(6-Methoxynaphthalen-2-yloxy)butoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-39-3P, 3-[4-[3-(Biphenyl-4-yloxy)propoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-40-6P, 3-[4-[3-(Biphenyl-3-yloxy)propoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-41-7P, 3-[4-[3-(6-Methoxynaphthalen-2-yloxy)propoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid 478546-48-4P, 3-[4-[3-(4-Phenoxyphenoxy)propoxy]-2-[[(2-pyridylcarbonyl)amino]methyl]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR modulator; preparation of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

RN 478546-21-3 CAPLUS
CN Benzenepropanoic acid, 4-[2-([1,1'-biphenyl]-4-yloxy)ethoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-22-4 CAPLUS
CN Benzenepropanoic acid, 4-[2-([1,1'-biphenyl]-3-yloxy)ethoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-23-5 CAPLUS
CN Benzenepropanoic acid, 4-[2-(4-phenoxyphenoxy)ethoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-24-6 CAPLUS
CN Benzenepropanoic acid, 4-[2-[(3-phenyl-6-benzofuranyl)oxy]ethoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-25-7 CAPLUS
CN Benzenepropanoic acid, 4-[2-[(6-methoxy-2-naphthalenyl)oxy]ethoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-32-6 CAPLUS
CN Benzenepropanoic acid, 4-[4-([1,1'-biphenyl]-3-yloxy)butoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-33-7 CAPLUS
CN Benzenepropanoic acid, 4-[4-(4-phenoxyphenoxy)butoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-34-8 CAPLUS
CN Benzenepropanoic acid, 4-[4-[(3-phenyl-6-benzofuranyl)oxy]butoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-35-9 CAPLUS
CN Benzenepropanoic acid, 4-[4-[(6-methoxy-2-naphthalenyl)oxy]butoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-39-3 CAPLUS
CN Benzenepropanoic acid, 4-[3-([1,1'-biphenyl]-4-yloxy)propoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-40-6 CAPLUS
CN Benzenepropanoic acid, 4-[3-([1,1'-biphenyl]-3-yloxy)propoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-41-7 CAPLUS
CN Benzenepropanoic acid, 4-[3-[(6-methoxy-2-naphthalenyl)oxy]propoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



RN 478546-48-4 CAPLUS
CN Benzenepropanoic acid, 4-[3-(4-phenoxyphenoxy)propoxy]-2-[[(2-pyridinylcarbonyl)amino]methyl]- (CA INDEX NAME)



GI



I



II

AB Title compds. I [wherein n = 2-5; V = a bond or O; X = CH2 or O; p = 0 or 1; m = 1-4; Y1 = (un)substituted (hetero)aryl; Y2 and Y3 = independently H, alkyl, or alkoxy; Y4 = (un)substituted alk(en/yn)ylaminoalkyl, carboxyaminoalkyl, (thio)ureidoalkyl, carbamoylalkyl, aminoalkyl, alkoxyalkyl, alkylthioalkyl, or CN; R5 = H or alkyl; and pharmaceutically acceptable salts, solvates, hydrates, or stereoisomers thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators (no data). For example, 3-[2-(1,3-dioxo-1,3-dihydroisoindolo-2-ylmethyl)-4-hydroxyphenyl]propionic acid tert-Bu ester was coupled with toluene-4-sulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester in the presence of Cs2CO3 in DMF. Deprotection of the amine using NaBH4 in isopropanol followed by conversion to the carbamate and deesterification gave II. I are useful for the treatment of Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X, as well as cardiovascular diseases (no data).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:2234 CAPLUS
DOCUMENT NUMBER: 126:31271
TITLE: Preparation of pyridine moiety-containing sulfonamide compounds as pharmaceuticals
INVENTOR(S): Tatsugami, Shinichi; Oonishi, Hiroyuki; Morimoto, Katsumi
PATENT ASSIGNEE(S): Terumo Corp, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08245590	A	19960924	JP 1995-49789	19950309

PRIORITY APPLN. INFO.: JP 1995-49789 19950309
OTHER SOURCE(S): MARPAT 126:31271
IT 184419-32-7P 184653-31-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridine moiety-containing sulfonamide compds. as pharmaceuticals)
RN 184419-32-7 CAPLUS
CN Benzenepropanoic acid, 4-[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]-4-phenyl-4-(3-pyridinyl)butyl]-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184653-31-4 CAPLUS
CN Benzenepropanoic acid, 4-[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]-4-phenyl-4-(3-pyridinyl)butyl]-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 184419-61-2P 184419-62-3P 184419-63-4P
184653-33-6P 184653-34-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridine moiety-containing sulfonamide compds. as pharmaceuticals)

RN 184419-61-2 CAPLUS
CN Benzenepropanoic acid, 4-[1-cyano-4-phenyl-4-(3-pyridinyl)butyl]-, methyl ester (CA INDEX NAME)



RN 184419-62-3 CAPLUS
CN Benzenepropanoic acid, 4-[1-(aminomethyl)-4-phenyl-4-(3-pyridinyl)butyl]-, methyl ester, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184419-63-4 CAPLUS
CN Benzenepropanoic acid, 4-[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]-4-phenyl-4-(3-pyridinyl)butyl]-, methyl ester, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184653-33-6 CAPLUS
CN Benzenepropanoic acid, 4-[1-(aminomethyl)-4-phenyl-4-(3-pyridinyl)butyl]-, methyl ester, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 184653-34-7 CAPLUS
CN Benzenepropanoic acid, 4-[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]-4-phenyl-4-(3-pyridinyl)butyl]-, methyl ester, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I



II

AB The title compds. I [X = H, halo, etc.; Z = O(CH2)mCH, etc.; R = (CH2)nCO2R', etc.; n, m = 0 - 4; R' = alkyl, H], useful as platelet aggregation and allergy inhibitors, are prepared The title compound II in vitro showed IC50 of 0.039 x 10-6 M against U-46619-induced platelet aggregation.

L9 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:509478 CAPLUS
DOCUMENT NUMBER: 125:167791
TITLE: Preparation of pyridylalkylphenylsulfone derivatives as antithrombotic agents and antiallergic agents
INVENTOR(S): Ohnishi, Hiroyuki; Morimoto, Katsumi; Kitamura, Harue; Kasukawa, Hiroaki
PATENT ASSIGNEE(S): Terumo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619454	A1	19960627	WO 1995-JP2590	19951218
W: AU, CA, CN, JP, KR, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9641892	A	19960710	AU 1996-41892	19951218
PRIORITY APPLN. INFO.:			JP 1994-316279 A	19941220
			WO 1995-JP2590 W	19951218

OTHER SOURCE(S): MARPAT 125:167791
IT 180153-37-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of pyridylalkylphenylsulfone derivs. as thromboxane A2 inhibitors)
RN 180153-37-1 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-4-(3-pyridinyl)butyl]- (CA INDEX NAME)



IT 180153-38-2P 180153-39-3P 180153-40-6P
180153-41-7P 180153-42-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of pyridylalkylphenylsulfone derivs. as thromboxane A2 inhibitors)
RN 180153-38-2 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-4-(3-pyridinyl)butyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 180153-39-3 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-5-(3-pyridinyl)pentyl]- (CA INDEX NAME)



RN 180153-40-6 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-6-(3-pyridinyl)hexyl]- (CA INDEX NAME)



RN 180153-41-7 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-(phenylsulfonyl)ethyl]-4-(3-pyridinyl)butyl]- (CA INDEX NAME)





RN 180153-42-8 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-[(4-methylphenyl)sulfonyl]ethyl]-4-(3-pyridinyl)butyl]- (CA INDEX NAME)



IT 180153-36-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of pyridylalkylphenylsulfone derivs. as thromboxane A2 inhibitors)
RN 180153-36-0 CAPLUS
CN Benzenepropanoic acid, 4-[1-[2-[(4-chlorophenyl)sulfonyl]ethyl]-4-(3-pyridinyl)butyl]-, ethyl ester (CA INDEX NAME)



GI



I

AB The title compds. I [X = H, OH, NO2, CN, CF3, halo, lower alkyl, lower alkoxy; R = O(CH2)aCO2R1, (CH2)aCO2R1, CR2:CR3CO2R1 or CR2R3CR4R5CO2R1 (R1, R2, R3, R4, R5 = H, lower alkyl;, a = 0-5); h, m, n = 0-5] are prepared A medicinal preparation containing I is also claimed. I possessing thromboxane A2 and prostaglandin H2 antagonisms and the effect of inhibiting the synthesis of thromboxane A2, is useful as an antithrombotic agent and an antiallergic agent. Thus, I [X = p-Cl; R = (CH2)2CO2H; h = 2; m = 0; n = 3] was prepared from p-HCOC6H4CH(OEt)2 in twelve steps and demonstrated a IC50 against thromboxane A2 of 0.25 μM.

L9 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:457766 CAPLUS
DOCUMENT NUMBER: 125:114597
TITLE: Preparation of azole derivatives as leukotriene and thromboxane A2 antagonists
INVENTOR(S): Nagaoka, Hitoshi; Yokota, Masaki; Akane, Hiroaki; Arakida, Yasuhito; Isomura, Yasuo
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611916	A1	19960425	WO 1995-JP2085	19951012
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2202623	A1	19960425	CA 1995-2202623	19951012
AU 9536730	A	19960506	AU 1995-36730	19951012
AU 699476	B2	19981203		
EP 786457	A1	19970730	EP 1995-934280	19951012
EP 786457	B1	20020529		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1160397	A	19970924	CN 1995-195649	19951012
CN 1107059	B	20030430		
HU 77609	A2	19980629	HU 1997-2271	19951012
TW 381088	B	20000201	TW 1995-84110701	19951012
JP 3061862	B2	20000710	JP 1996-513092	19951012
RU 2161612	C2	20010110	RU 1997-107457	19951012
AT 218132	T	20020615	AT 1995-934280	19951012
FI 9701510	A	19970411	FI 1997-1510	19970411
NO 9701685	A	19970613	NO 1997-1685	19970411
NO 309268	B1	20010108		
US 5981559	A	19991109	US 1997-809466	19970815

PRIORITY APPLN. INFO.:	JP 1994-249488	A	19941014
	JP 1994-251121	A	19941018
	WO 1995-JP2085	W	19951012

OTHER SOURCE(S): MARPAT 125:114597
IT 179103-10-7P 179103-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole derivs. as leukotriene and thromboxane A2 antagonists for disease therapy)
RN 179103-10-7 CAPLUS
CN Acetic acid, [4-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-[[[6-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-2-pyridinyl]carbonyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179103-23-2 CAPLUS
CN Acetic acid, [4-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-[[[6-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]-2-pyridinyl]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



GI



I

AB Thiazole- or oxazole-containing benzanilide derivs. represented by general formula [I; R1, R2 = H, cycloalkyl, (un)substituted lower alkyl, (un)substituted aryl; or R1R2 = CH:CHCH:CH or (CH2)4 to complete a condensed ring which may be substituted by optionally substituted lower alkyl, amino, etc.; R3, R6, R7, R8 = H, amino, cyano, NO2, OH, halo, lower alkoxy, (un)substituted lower alkyl; R4 = cyano, tetrazolyl, CO2H or its ester, E-NH-F-R10; wherein E = single bond, CO; F = single bond, lower alkylene; R10 = H, CONH2, mono- or dialkylcarbamoyl, CO2H, lower alkoxycarbonyl, optionally alkyl-substituted arylcarbonyl, lower alkanoyl, lower alkylsulfonyl, optionally alkyl-substituted arylsulfonyl; R5 = H or lower alkyl; D = optionally substituted lower alkylene; X, Z = O, S; Y = N, CH; A O-B, B-O, S-B, B-S or B (wherein B = lower alkylene or lower alkenylene); n = 0, 1 or 2] or pharmaceutically acceptable salts thereof, are prepared These compds. I have both of a leukotriene antagonistic effect and a thromboxane A2 antagonistic effect and are useful in preventing or treating allergic diseases (in particular, bronchial asthma, allergic rhinitis, or nettle rash), ischemic heart diseases, or ischemic brain diseases. Thus, a thiazole containing benzanilide derivative (II; R = H, R1 = Ph, A = CH:CH) (preparation given) was dissolved in DMF, treated successively with K2CO3, Bu4NBr, and Et bromoacetate, and stirred at room temperature for 12 h to give the title compound II (R = CH2CO2Et, R1 = Ph, A = CH:CH). II (R = CH2CO2H, R1 = CMe3, A = CH2O) showed IC50 of 0.055 μM for inhibiting the U-46619 (stable analog of thromboxane A2)-induced aggregation of guinea pig's platelet rich plasma. II (R = CH2CO2H, R1 = cyclobutyl, A = CH2O) at 10 mg/kg p.o. in vivo inhibited by 72% the U-46619-induced respiratory tract resistance in guinea pigs.

L9 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:427840 CAPLUS
DOCUMENT NUMBER: 119:27840
TITLE: Preparation of phenoxyacetic acids and TXA2 antagonists containing them
INVENTOR(S): Maeda, Sachiko; Igarashi, Azuma; Sugizaki, Katsuyoshi; Suzuki, Myoshi; Ozawa, Shinji
PATENT ASSIGNEE(S): Terumo Corp, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05032613	A	19930209	JP 1991-188730	19910729

PRIORITY APPLN. INFO.: JP 1991-188730 19910729
OTHER SOURCE(S): MARPAT 119:27840
IT 148066-76-6P 148066-77-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as TXA2 antagonist)
RN 148066-76-6 CAPLUS
CN Acetic acid, [4-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-[(2-pyridinylcarbonyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 148066-77-7 CAPLUS
CN Acetic acid, [4-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-[[3-(2-pyridinylmethoxy)benzoyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. I (A = Me, Ph, 2-pyridyl; R1 = H, Me, Et; R2 = H, phenyl-, pyridyl-, naphthyl-lower-alkoxy; X = H, halo, lower alkyl, CF3, alkoxy, OH, cyano; n = 0-2) or their physiol. acceptable salts, useful as therapeutic and prophylactic antiallergy agents and antithrombotics, are prepared Treatment of 4-[3-(4-chlorobenzenesulfonyl)propyl]-2-benzoylaminophenol (preparation given) with Et bromoacetate and K2CO3 in acetone at room temperature for 5 h gave 94% Et 4-[3-(4-chlorobenzenesulfonyl)propyl]-2-(benzoylamino)phenoxyacetate, which was hydrolyzed with 2N NaOH in THF at 0° for 2.5 h to afford 95% 4-[3-(4-chlorobenzenesulfonyl)propyl]-2-(benzoylamino)phenoxyacetic acid. The product inhibited U-46619-induced smooth muscle contraction with IC50 of 5.7 + 10-9 M. LD50 of several phenoxyacetates was >300 mg/kg p.o. in male mice.

L9 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:590030 CAPLUS
DOCUMENT NUMBER: 109:190030
TITLE: Phenoxycaproic acid derivatives for treatment of hyperlipemia and geriatric diorders
INVENTOR(S): Kawakami, Mari; Yoneda, Seiji; Morishita, Shinichi; Saito, Takashi
PATENT ASSIGNEE(S): Kyushin Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63104939	A	19880510	JP 1986-247510	19861020
JP 05088693	B	19931224		

PRIORITY APPLN. INFO.: JP 1986-247510 19861020
OTHER SOURCE(S): CASREACT 109:190030; MARPAT 109:190030
IT 113795-23-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antihyperlipemic and geriatric disease agent)
RN 113795-23-6 CAPLUS
CN Hexanoic acid, 2,2-dimethyl-6-[4-(4-phenylbutyl)phenoxy]-, 3-pyridinylmethyl ester (CA INDEX NAME)



GI



I

AB Title derivs. I (R1, R2 = H, Me; R3 = H, Me, Et, 3-pyridinylmethyl, 2-methyl-5-piperazinylmethyl) are prepared 4-(4-Phenylbutyl)phenol was stirred in a suspension of THF containing NaH, then 1-bromo-4-chlorobutane was added and the mixture was refluxed for 10 h to give 84% 4-[4-(4-phenylbutyl)phenoxy]butyl chloride, which was treated with lithiated Na isobutyrate at room temperature for 4 h to give 76% I (R1 = R2 = R3 = H) (II). Rats were orally fed for 2 wk with a high-fat diet containing cholesterol 1, bile acid 1, and cottonseed oil 6% and 100 mg/kg-day II was administered orally to show total cholesterol, high-d. lipoprotein cholesterol in blood, and liver weight of the rats to be (138.4 ± 8.0) mg/dL, (51.2 ± 2.3) mg/dL, and (51.4 ± 2.0) mg/g-body weight, resp., vs., 325.6 ± 48.3, 43.8 ± 4.5, and 57.2 ± 2.1, resp., for a control, 238.9 ±

15.5, 56.7 ± 5.0, 59.6 ± 1.8, resp., for gemfibrozil, and 176.8 ± 15.5, 40.6 ± 5.1, and 57.8 ± 2.0, resp., for clofibrate.

L9 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:221371 CAPLUS
DOCUMENT NUMBER: 108:221371
TITLE: Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives
AUTHOR(S): Morishita, Shinichi; Saito, Takashi; Hirai, Yasuharu; Shoji, Masamichi; Mishima, Yasuhiro; Kawakami, Masato
CORPORATE SOURCE: Res. Lab., Kyushin Pharm. Co., Ltd., Tokyo, 166, Japan
SOURCE: Journal of Medicinal Chemistry (1988), 31(6), 1205-9
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:221371
IT 113795-23-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipidemic activity of)
RN 113795-23-6 CAPLUS
CN Hexanoic acid, 2,2-dimethyl-6-[4-(4-phenylbutyl)phenoxy]-, 3-pyridinylmethyl ester (CA INDEX NAME)



GI



AB A series of 2-substituted isobutyric acid derivs., e.g. I (n = 0-6, m = 3-10, R = H; n = m = 4, R = 3-pyridylmethyl, 3-methyl-5-pyrazinylmethyl), have been synthesized and evaluated as hypolipidemic agents. I (n = m = 4, R = H, 3-pyridylmethyl) were found to decrease the level of plasma total cholesterol in exptl. hyperlipemic rats to a greater extent than clofibrate (CF) and to increase the level of plasma high-d. lipoprotein cholesterol to the same extent as gemfibrozil (GF). Increases in liver weight caused by these compds. were less than those with CF and GF.

L9 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:22564 CAPLUS
Correction of: 1978:475314
DOCUMENT NUMBER: 90:22564
Correction of: 89:75314
ORIGINAL REFERENCE NO.: 90:3715a,3718a
TITLE: Substituted 2-propanol derivatives and their nicotinic acid esters
INVENTOR(S): Grill, Helmut; Zschocke, Rainer H.; Wagner, Josef; Hofrichter, Gernot; Janiak, P. Stefan
PATENT ASSIGNEE(S): Chemisch-Pharmazeutische Fabrik Adolf Klinge und Co., Fed. Rep. Ger.
SOURCE: Ger. Offen., 41 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2460689	A1	19760701	DE 1974-2460689	19741220
DE 2460689	B2	19791018		
DE 2460689	C3	19800626		
CA 1065870	A1	19791106	CA 1975-241890	19751211
DD 123597	A5	19770105	DD 1975-190187	19751216
CH 622487	A5	19810415	CH 1975-16303	19751216
DK 7505732	A	19760621	DK 1975-5732	19751217
SE 7514271	A	19760621	SE 1975-14271	19751217
NL 7514696	A	19760622	NL 1975-14696	19751217
NL 171356	B	19821018		
NL 171356	C	19830316		
FR 2294691	A1	19760716	FR 1975-38741	19751217
FR 2294691	B1	19780728		
AU 7587623	A	19770623	AU 1975-87623	19751217
ZA 7507912	A	19761229	ZA 1975-7912	19751218
US 4073935	A	19780214	US 1975-641982	19751218
AT 7509643	A	19790315	AT 1975-9643	19751218
AT 352699	B	19791010		
BE 836870	A1	19760416	BE 1975-162937	19751219
GB 1516747	A	19780705	GB 1975-52228	19751219
HU 173345	B	19790428	HU 1975-KI732	19751219
JP 51125238	A	19761101	JP 1975-152705	19751220
PL 97422	B1	19780228	PL 1975-185748	19751220
JP 57005770	B	19820201	JP 1976-3979	19760116
GB 1531695	A	19781108	GB 1977-24008	19770608
GB 1533820	A	19781129	GB 1977-24010	19770608
US 4109013	A	19780822	US 1977-849766	19771109
US 4144351	A	19790313	US 1977-849765	19771109
AT 7802641	A	19790315	AT 1978-2641	19780414

PRIORITY APPLN. INFO.:

DE 1974-2460689	A	19741220
AT 1975-9643	A	19751218
US 1975-641982	A3	19751218
GB 1975-52228	A	19751219
DE 1976-2625688	A	19760608
DE 1976-2625689	A	19760608

OTHER SOURCE(S): MARPAT 90:22564
IT 60377-85-7P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)
RN 60377-85-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-(4-chlorophenoxy)-1-[[4-(3-methoxy-3-oxopropyl)phenoxy]methyl]ethyl ester (CA INDEX NAME)



AB 4-RC6H4ZCH2CH(OH)CH2Z1C6H4R1 (I; R = Cl, CMe3; R1 = CO2Me, CH:CHCO2Me, CONHOH, 1,3-dioxolan-2-yl, etc.; Z, Z1 = O, S, NH) and their nicotinate esters were prepared by the reaction of a phenol with a phenoxyepoxypropane or an aniline with a chloropropanol. Thus, 4-HOC6H4CO2Me was refluxed with 3-(4-chlorophenoxy)-1,2-epoxypropane in KOH-MeOH for 21 h to give 74.4% I (R = Cl, R1 = CO2Me, Z = Z1 = O) (II). About 120 I were prepared having hypolipemic activity, e.g., II showed 63.8 ± 17.2% serum triglyceride lowering in the rat.

L9 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:475314 CAPLUS
Correction of: 1976:523579
DOCUMENT NUMBER: 89:75314
Correction of: 85:123579
ORIGINAL REFERENCE NO.: 89:11571a,11574a
TITLE: Substituted 2-propanol derivatives and their nicotinic acid esters
INVENTOR(S): Grill, Helmut; Zschocke, Rainer H.; Wagner, Josef; Hofrichter, Gernot; Janiak, P. Stefan
PATENT ASSIGNEE(S): Chemisch-Pharmazeutische Fabrik Adolf Klinge und Co., Fed. Rep. Ger.
SOURCE: Ger. Offen., 41 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2460689		19760701	DE 1974-2460689	19741220

IT 60377-85-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipemic activity of)
RN 60377-85-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-(4-chlorophenoxy)-1-[[4-(3-methoxy-3-oxopropyl)phenoxy]methyl]ethyl ester (CA INDEX NAME)



AB 4-RC6H4ZCH2CH(OH)CH2Z1C6H4R1 (I; R = Cl, Me3C; R1 = CO2Me, CH:CHCO2Me, CONHOH, 1,3-dioxolan-2-yl, etc.; Z, Z1 = O, S, NH) and their nicotinate esters were prepared by the reaction of a phenol with a phenoxyepoxypropane or an aniline with a chloropropanol. Thus, 4-HOC6H4CO2Me was refluxed with 3-(4-chlorophenoxy)-1,2-epoxypropane in KOH-MeOH for 21 h to give 74.4% I (R = Cl, R1 = 4-CO2Me, Z = Z1 = O) (II). About 120 I were prepared having hypolipemic activity, e.g., II showed 63.8 ± 7.2% serum triglyceride lowering in the rat.

L9 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:523579 CAPLUS
DOCUMENT NUMBER: 85:123579
ORIGINAL REFERENCE NO.: 85:19829a,19832a
TITLE: Substituted 2-propanol derivatives and their nicotinic acid esters
INVENTOR(S): Grill, Helmut; Zschocke, Rainer H.; Wagner, Josef; Hofrichter, Gernot; Janiak, P. Stefan
PATENT ASSIGNEE(S): Chemisch-Pharmazeutische Fabrik Adolf Klinge und Co., Fed. Rep. Ger.
SOURCE: Ger. Offen., 41 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2560689		19760701	DE 1974-2460689	19741220

IT 60377-85-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60377-85-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-(4-chlorophenoxy)-1-[[4-(3-methoxy-3-oxopropyl)phenoxy]methyl]ethyl ester (CA INDEX NAME)



AB 4-RC6H4ZCH2CH(OH)CH2Z1C6H4R1 (I; R = Cl, Me3C; R1 = CO2Me, CH:CHCO2Me, CONHOH, 1,3-dioxolan-2-yl, etc.; Z, Z1 = O, S, NH) and their nicotinate esters were prepared by the reaction of a phenol with a phenoxyepoxypropane or an aniline with a chloropropanol. Thus, 4-HOC6H4CO2Me was refluxed with 3-(4-chlorophenoxy)-1,2-epoxypropane in KOH-MeOH for 21 hr to give 74.4% I (R = Cl, R1 = CO2Me, Z = Z1 = O) (II). About 120 I were prepared having hypolipemic activity, e.g., I showed 63.8 ± 17.2% serum triglyceride lowering in the rat.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.57	276.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.40	-10.40

STN INTERNATIONAL LOGOFF AT 12:41:37 ON 26 FEB 2008